NAMS vs. JAZZ, BPMC, IONS, OGN, BBIO, CYTK, APLS, MDGL, ALPN, and NUVL
Should you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), Ionis Pharmaceuticals (IONS), Organon & Co. (OGN), BridgeBio Pharma (BBIO), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), Alpine Immune Sciences (ALPN), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical preparations" industry.
NewAmsterdam Pharma (NASDAQ:NAMS) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation.
In the previous week, Jazz Pharmaceuticals had 6 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 10 mentions for Jazz Pharmaceuticals and 4 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.90 beat Jazz Pharmaceuticals' score of 0.45 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.
89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 19.5% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 4.4% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
NewAmsterdam Pharma currently has a consensus price target of $33.25, suggesting a potential upside of 77.33%. Jazz Pharmaceuticals has a consensus price target of $192.75, suggesting a potential upside of 83.14%. Given Jazz Pharmaceuticals' higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than NewAmsterdam Pharma.
Jazz Pharmaceuticals received 1086 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 80.56% of users gave Jazz Pharmaceuticals an outperform vote.
Jazz Pharmaceuticals has a net margin of 8.61% compared to NewAmsterdam Pharma's net margin of 0.00%. Jazz Pharmaceuticals' return on equity of 27.86% beat NewAmsterdam Pharma's return on equity.
Jazz Pharmaceuticals has higher revenue and earnings than NewAmsterdam Pharma.
NewAmsterdam Pharma has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.
Summary
Jazz Pharmaceuticals beats NewAmsterdam Pharma on 10 of the 16 factors compared between the two stocks.
Get NewAmsterdam Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NewAmsterdam Pharma Competitors List
Related Companies and Tools
